Shilpa Medicare launches branded generic anticancer drug Dasatinib

Shilpa Medicare Limited has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name 'DASASHIL'.

DASASHIL is first branded generic anticancer drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of chronic myeloid leukaemia (CML).

Current, monthly therapy cost of innovator is approximately 1.65 lacs. With the launch of DASASHIL, monthly cost of treatment will be reduced drastically to Rs. 6440.

DASAHIL will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability.
The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.

Today, there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by DASASHIL tablets.

Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=123671&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

High-end diagnostics changing the face of medical testing industry

Bigger players in space are getting into sophisticated high end testing, oncology testing, reproductive genetics and other specialised fields, while maintaining basic testing as a revenue safety net Last month, Strand Life Sciences, a Bengaluru-based specialty diagnostic company, bought the India operations of US-based  medical diagnostic  company, Quest Diagnostic. The takeover created ripples in the  medical diagnostic  industry in India. Quest had set shop some ten years ago and has an established routine testing business with many corporate clients. Strand is actually a spinoff from IISc Bangalore as a bioinformatics company. It bought out HCG’s diagnostic business in January, with a focus on oncology testing and now with Quest, it is emerging as a sophisticated end-to-end operator. The Quest acquisition offers a new service line, of routine testing, which is 80-90 per cent of the diagnostic market. The deal could make Strand a leader in the testing busine...
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first th...
Read more